You are here: Industry Insights > Sugemalimab

News List

On sale with the unit price of CNY 12,375/bottle, Sugemalimab is planning to file for a third indication PharmaSources/Yi
January 24, 2022
Recently, Sugemalimab (trade name: Cejemly®), Stone Pharma PD-L1 monoclonal antibody, is on sale in China. It is reported that its public retail price is CNY 12,375/bottle (600mg/20ml) (tax included).
CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients prnasia
January 19, 2022
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines...
CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment prnasia
January 18, 2022
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines...
CStone announces the clinical data from registrational study of Sugemalimab in stage III non-small cell lung cancer published in The Lancet Oncology prnasia
January 17, 2022
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines...
CStone announces phase 2 GEMSTONE-201 trial met primary endpoint of objective response rate (ORR) in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) prnasia
January 13, 2022
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines...
CStone presents updated data from registrational clinical study of sugemalimab in patients with stage IV NSCLC in an oral presentation at IASLC 2021 WCLC prnasia
September 28, 2021
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focus on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines...
EQRx signs $1.8bn merger deal with CM Life Sciences III pharmaceutical-technology
August 10, 2021
Pharmaceutical company EQRx and a life science-focused special purpose acquisition company (SPAC), CM Life Sciences III, have signed a definitive business combination agreement worth up to $1.8bn.
Anti-PD-L1 monoclonal antibody shows promise in lung cancer patient europeanpharmaceuticalreview
May 31, 2021
In a Phase III trial sugemalimab meaningfully improved progression free survival in patients with stage III non-small cell lung cancer (NSCLC).
CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application prnasia
May 28, 2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, today announced that a registrational clinical trial ...
CStone Pharmaceuticals Announces China's NMPA has Accepted its New Drug Application for anti-PD-L1 Monoclonal Antibody Sugemalimab in First-Line Advanced NSCLC prnasia
November 12, 2020
CStone Pharmaceuticals, a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, announced that China's National Medical Products Administration (NMPA) has accepted ..

Previous page 1 2 Next page